Filagra, which is present in the commercial agent Fildena, used for the treatment of erectile dysfunction, specifically inhibits the breakdown of cellular cGMP by PDE5 ( 33 ) and thereby prolongs and enhances the effects of the NO/cGMP pathway. The end-of-treatment mean scores for Q3 (ability to achieve an erection), Q4 (ability to maintain an erection), and Q7 (satisfaction with treatment) of the